Physician profile
Lauren Dobson
NPI 1306536842
$1,177.11
in general payments reported to CMS, 2019-2025
22 companies · $555 in 2025
The $555 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $201 · 2024: $421 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,177.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $268.39 | 2023-2025 | |
| Amgen INC. | $139.76 | 2023-2025 | Evenity, Prolia, Prolia |
| Vertex Pharmaceuticals Incorporated | $103.35 | 2024-2025 | |
| Pfizer INC. | $77.11 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $76.65 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $76.63 | 2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.16 | 2023-2025 | Synjardy, Tradjenta, Jardiance |
| Lilly USA, LLC | $64.17 | 2024-2025 | Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $60.61 | 2024-2025 | Airsupra |
| Ardelyx, INC. | $30.83 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $30.29 | 2023 | |
| Janssen Pharmaceuticals, INC | $22.58 | 2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $21.37 | 2023 | |
| Verona Pharma, INC. | $20.31 | 2025 | Ohtuvayre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.16 | 2025 | Caplyta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $16.70 | 2025 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.16 | 2024 | Xifaxan |
| Lundbeck LLC | $14.89 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $14.46 | 2023 | Nexletol |
| Glaxosmithkline, LLC. | $14.06 | 2023 | Shingrix, Arexvy |
| Vanda Pharmaceuticals INC. | $13.40 | 2024 | Hetlioz, Fanapt |
| Phathom Pharmaceuticals, INC. | $9.07 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Dobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.